Untitled

Samsa, Greg; Matchar, David B.; Dolor, Rowena J; Wiklund, Ingela; Hedner, Ewa; Wygant, Gail; Hauch, Ole; Marple, Cheryl Beadle; Edwards, Roger

doi:10.1186/1477-7525-2-22

Cited by 75 publications

(66 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OAC treatment satisfaction was assessed using the Duke Anticoagulation Satisfaction Scale 28 (DASS), which was administered at all four survey time points. The DASS was developed to measure the quality of life (QOL) and satisfaction among patients receiving OAC treatment.…”

Section: Methodsmentioning

confidence: 99%

Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy

Stephenson¹,

Shinde²,

Kwong³

et al. 2018

PPA

View full text Add to dashboard Cite

ObjectiveTo compare oral anticoagulant (OAC) adherence among patients with nonvalvular atrial fibrillation (NVAF) using patient-reported and claims-based measures, and to evaluate the effect of OAC adherence on health care costs and patient satisfaction with OAC therapy.MethodsThis was a hybrid US observational study consisting of a longitudinal cohort survey followed by linkage and analysis of respondents’ administrative claims data. Patients with NVAF receiving warfarin, dabigatran, rivaroxaban, or apixaban completed an initial survey and follow-up surveys at 4, 8, and 12 months. Patient-reported adherence was measured at each survey by Morisky Medication Adherence Scale (MMAS-8) and pharmacy claims-determined adherence by the proportion of days covered (PDC) for the 12-month period following the initial survey date; adherence was defined as MMAS-8 score =8 and PDC ≥80%. Patient satisfaction with OAC therapy was assessed by the Duke Anticoagulation Satisfaction Scale (DASS).ResultsOverall, 675 patients completed at least the initial survey (warfarin, n=271; dabigatran, n=266; rivaroxaban, n=128; apixaban, n=10). Fewer than half (47.9%) were PDC adherent, 37.2% were MMAS-8 adherent, and 19.4% were adherent by both measures. Total medical costs of PDC-adherent patients were significantly lower vs PDC-nonadherent patients (US$640 vs $993 per-patient per-month, respectively, p<0.05). MMAS-8-adherent patients reported higher treatment satisfaction; total DASS score was significantly lower among MMAS-8-adherent than MMAS-8-nonadherent patients (37.3 vs 42.9, respectively, p<0.001).ConclusionUsing claims-based or patient-reported methods to measure OAC adherence may lead to different results when assessing impact on health care costs and satisfaction with anticoagulation medication. These results underscore the importance of considering both claims-based and patient-reported measures when evaluating treatment adherence in real-world settings.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy

Stephenson¹,

Shinde²,

Kwong³

et al. 2018

PPA

View full text Add to dashboard Cite

show abstract

“…These results suggest that the OMQoL is responsive to change over time. Nevertheless, instrument validation is a continuous process [22]. Further observational studies or clinical trials are required to evaluate the ability of OMQoL to detect outcome changes over time and to determine the range in minimal important differences (MID) for the OMQoL across all applications and patient samples [21].…”

Section: Discussionmentioning

confidence: 99%

A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation

Cheng

Leung

Liang

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Anticoagulation-specific questionnaire PACT-Q. The ‘Perception of AntiCoagulant Treatment Questionnaire’ was developed to assess patients’ expectations of, and satisfaction with their anticoagulant treatment [ 15 – 17 ].…”

Section: Methods and Designmentioning

confidence: 99%

The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry

et al. 2015

View full text Add to dashboard Cite

BackgroundVenous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement.Methods/designThe PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls.ResultsOverall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year.ConclusionThe PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice.Trial registrationRegistered in DRKS register, ID number: DRKS00004795

show abstract

Untitled

Cited by 75 publications

References 9 publications

Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy

Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy

A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation

The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry

Contact Info

Product

Resources

About